156973-09-0

Basic information

• Product Name: 3-Pyridinemethanamine,6-amino-(9CI)
• Synonyms: 3-Pyridinemethanamine,6-amino-(9CI);6-AMINO-3-PYRIDINEMETHANAMINE;5-(Aminomethyl)pyridin-2-amine, (6-Aminopyridin-3-yl)methylamine;5-AMinoMethyl-pyridin-2-ylaMine;5-Aminomethyl-2-aminopyridine;6-Amino-3-(aminomethyl)pyridine
• CAS NO: 156973-09-0
• Molecular Formula: C₆H₉N₃
• Molecular Weight: 123.16
• Product Categories: PYRIDINE;pharmacetical
• Mol File: 156973-09-0.mol

Chemical Properties

• Boiling Point: 292.649 °C at 760 mmHg
• Flash Point: 155.793 °C
• Appearance: /
• Density: 1.174 g/cm³
• Vapor Pressure: 0.002mmHg at 25°C
• Refractive Index: 1.624
• Storage Temp.: 2-8°C
• PKA: 8.23±0.29(Predicted)
• CAS DataBase Reference: 3-Pyridinemethanamine,6-amino-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinemethanamine,6-amino-(9CI)(156973-09-0)
• EPA Substance Registry System: 3-Pyridinemethanamine,6-amino-(9CI)(156973-09-0)

Safety Data

• Hazardous Substances Data: 156973-09-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
3-Pyridinemethanamine,6-amino-(9CI) is used as a reagent for studying aminopyridyl moiety-containing thrombin inhibitors. Its unique chemical structure allows it to interact with thrombin, a key enzyme in the blood clotting process, potentially leading to the development of novel anticoagulant drugs.
Used in Chemical Synthesis:
3-Pyridinemethanamine,6-amino-(9CI) can also be utilized as an intermediate in the synthesis of various pharmaceuticals and chemical products. Its versatile structure makes it a valuable building block for creating new molecules with specific properties and applications.

InChI:InChI=1/C6H9N3/c7-3-5-1-2-6(8)9-4-5/h1-2,4H,3,7H2,(H2,8,9)

Upstream product

• 187237-37-2 2-(tert-butoxycarbonyl-amino)-5-aminomethylpyridine 
• 902837-44-9 tert-butyl (5-cyanopyridin-2-yl)carbamate 
• 4214-73-7 6-aminonicotinonitrile 
• 329-89-5 6-aminonicotinic amide 

Downstream Products

• 1180132-17-5 5-((4-ethylpiperazin-1-yl)methyl)-6-methylpyridin-2-amine 
• 1363130-82-8 1-[(6-aminopyridin-3-yl)methyl]-3-[4-(benzenesulfonyl)phenyl]urea 
• 1138321-45-5 6-{-4-[3-(6-Aminopyridin-3-ylmethyl)ureido]phenyl}-2-ethylamino-N-methylnicotinamide 
• 183853-45-4 ((R)-1-{(S)-2-[(6-Amino-pyridin-3-ylmethyl)-carbamoyl]-pyrrolidine-1-carbonyl}-2,2-dicyclohexyl-ethyl)-carbamic acid tert-butyl ester 
• 183853-48-7 ((R)-1-{(S)-2-[(6-Amino-pyridin-3-ylmethyl)-carbamoyl]-pyrrolidine-1-carbonyl}-2,2-diphenyl-ethyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

Pyridine methylamine compound and preparation method thereof

The invention provides a pyridine methylamine compound and a preparation method thereof. The preparation method comprises the steps that tetrahydrofuran and sodium borohydride are sequentially added into a cyanopyridine compound, then an iodine-containing tetrahydrofuran solution is dropwise added, a reaction is conducted at the temperature of 20-30 DEG C, and after dropwise adding is completed, stirring is carried out continuously; after the reaction is finished, methanol is added for refluxing, extracting and spin-drying are carried out to obtain the pyridine methylamine compound; wherein a functional group in the cyanopyridine compound is selected from chlorine, bromine, methyl, ethyl, amino or hydrogen; according to the preparation method, high-temperature and high-pressure special equipment does not need to be used, so that the preparation method is relatively safe, and dangerous accidents such as explosion and fire disasters are avoided; besides, the preparation method is relatively environment-friendly, recycling treatment of hazardous waste (used Raney nickel) is not involved, the economic benefit is relatively high, borane generated by the synthesis method is converted into boric acid esters in the post-treatment process, the treatment cost is low, and the harm to the environment is much small.

Method for preparing abemaciclib intermediate compound

The invention relates to a method for preparing an abemaciclib intermediate compound. The method comprises the following steps: fumaronitrile and nitromethane are subjected to condensation, hydrogenation cyclization is performed to obtain 2-amino-5-amino methylpyridine, and ring formation is performed on 2-amino-5-amino methylpyridine and N,N-bis(2-chloroethyl)ethylamine to prepare 5-(4-ethylpiperazine-1-yl)methyl-2-aminopyridine which can be used for preparing abemaciclib. Reagents with high price are not used, the atom economy is high, side reaction is less, the method is safe and high in product yield and purity, the raw materials are cheap and easily accessible, the operation is simple and convenient, and the cost is low.

Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors

Cancer metabolism and epigenetics are among the most intensely pursued research areas in anticancer drug discovery. Here we report the first small molecules that simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT) and histone deacetylase (HDAC), two important targets of cancer metabolism and epigenetics, respectively. Through iterative structure-based drug design, chemical synthesis, and biological assays, a highly potent dual NAMPT and HDAC inhibitor was successfully identified. Compound 35 possessed excellent and balanced activities against both NAMPT (IC50 = 31 nM) and HDAC1 (IC50 = 55 nM). It could effectively induce cell apoptosis and autophagy and ultimately led to cell death. Importantly, compound 35 showed excellent in vivo antitumor efficacy in the HCT116 xenograft model. This proof-of-concept study demonstrates the feasibility of discovering an inhibitor targeting cancer metabolism and epigenetics and provides an efficient strategy for multitarget antitumor drug discovery.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

NOVEL QUINOLINE DERIVATIVES

The invention relates to compounds represented by Formula (I): and to pharmaceutically acceptable salts or solvates of said compounds, wherein each of A, R3-8, X3, X5, m, and n are defined herein. The invention also relates to pharmaceutical compositions containing the compounds of Formula (I) and to methods of treating hyperproliferative disorders in a mammal by administering compounds of Formula (I).

2,3-methano-amino acid compounds

Compound of formula (I): wherein: n represents 2 or 3, R1represents optionally substituted alkyl, cycloalkyl or optionally substituted phenyl, R2represents amino, optionally substituted amidino, optionally substituted guanidino or optionally substituted isothioureido, Ar represents aryl or heteroaryl, X1represents hydroxy or optionally substituted amino, isomers thereof, and also salts thereof with a pharmaceutically acceptable acid or base, and which medicinal products containing the same/are useful as trypsin-related serine protease inhibitors.

Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position

A novel class of thrombin inhibitors incorporating aminopyridyl moieties at the P1 position has been discovered. Four of these thrombin inhibitors (13b,c,e and 14d) showed nanomolar potency (K(i) 0.8-12 nM), 300-1500-fold selectivity for thrombin compared with trypsin, and good oral bioavailability (F = 40-76%) in rats or dogs. The neutral P1 was expected to increase metabolic stability and oral absorption. Identification of this novel aminopyridyl group at P1 was a key step in our search for a clinical candidate.

Process for the preparation of 2-amino-5-aminomethyl-pyridine

2-Amino-5-aminomethyl-pyridine, of the formula STR1 can be prepared by reacting substituted methylene-glutaconic acid dinitrile of the formula STR2 having the meaning of R1 as given in the general description, at from 50° to 200° C., initially with from 3 to 20 mol of ammonia and then, in the presence of a hydrogenation catalyst, with hydrogen. The hydrogen is present an a partial pressure of from 10 to 250 bar. The reaction can be carried out with or without solvent.